Business Context and Reporting Period
Company: Biodesix, Inc. (BDSX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 24, 2025
Event: Notice of failure to satisfy Nasdaq continued listing requirements due to low stock price.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The report focuses exclusively on the status of the company's stock listing.
Material Changes
- Stock Price Deficiency: The closing bid price for Biodesix common stock remained below the minimum $1.00 per share requirement for 30 consecutive business days.
- Regulatory Action: The Nasdaq Listing Qualifications Staff issued a written notice of non-compliance with Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has an initial 180-day period to regain compliance, ending on September 22, 2025.
- Compliance Criteria: To cure the deficiency, the stock must close at or above $1.00 for 10 consecutive business days before the compliance date.
- Future Options: If compliance is not met by the deadline, the Company may be eligible for an additional 180-day period if it meets other listing standards. Otherwise, the stock faces delisting.
- Proposed Remedies: Management intends to consider a reverse stock split to increase the bid price, though there is no assurance such a split will be consummated or effective.
- Risk: There is no assurance the Company will regain compliance or maintain its listing on The Nasdaq Global Market.
Investor Verification Checklist
- Verify the current closing bid price of BDSX stock relative to the $1.00 threshold.
- Monitor the company's announcement regarding the potential implementation of a reverse stock split.
- Track the 10 consecutive business days required to demonstrate compliance before September 22, 2025.
- Review subsequent filings for updates on the delisting appeal process if the initial compliance period expires without resolution.